7-phenyl-1-(5-(furan-2-yl)-1,3,4-oxadiazol-2-yl)-heptan-1-one | 849798-79-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-phenyl-1-(5-(furan-2-yl)-1,3,4-oxadiazol-2-yl)-heptan-1-one
• 英文别名: 7-phenyl-1-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-heptan-1-one；1-[5-(Furan-2-yl)-1,3,4-oxadiazol-2-yl]-7-phenylheptan-1-one
• CAS: 849798-79-4
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: FKFVIVTXKDACMG-UHFFFAOYSA-N

物化性质

• 沸点：
  489.1±47.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  69.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-呋喃甲酰肼 在 三乙胺 、 对甲苯磺酰氯 作用下， 生成 7-phenyl-1-(5-(furan-2-yl)-1,3,4-oxadiazol-2-yl)-heptan-1-one
  参考文献：
  名称：

  Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity

  摘要：

  The concurrent implementation of a proteome-wide serine hydrolase selectivity screen with traditional efforts to optimize fatty acid amide hydrolase (FAAH) inhibition potency led to the expedited discovery of a new class of exceptionally potent (K-i < 300 pM) and unusually selective (> 100-fold selective) inhibitors. The iterative inhibitor design and evaluation with assistance of the selectivity screen served to differentiate otherwise indistinguishable inhibitors permitting the simultaneous optimization of potency and selectivity. Significantly, the simultaneous assessment of all potential competitive enzymes with the selectivity screen does not require the use of expressed or purified enzymes or a competitive substrate, no modification of the inhibitors is required, and the relative potency for competitive enzymes can be quantified (IC50's) including those that lack known substrates or function. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.085

文献信息

• Optimization of the Central Heterocycle of α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase
  作者：Joie Garfunkle、Cyrine Ezzili、Thomas J. Rayl、Dustin G. Hochstatter、Inkyu Hwang、Dale L. Boger

  DOI：10.1021/jm800136b

  日期：2008.8.1

  The synthesis and evaluation of a refined series of alpha-ketoheterocycles based on the oxazole 2 (OL-135) incorporating systematic changes in the central heterocycle bearing a key set of added substituents are described. The nature of the central heterocycle, even within the systematic and minor perturbations explored herein, significantly influenced the inhibitor activity: 1,3,4-oxadiazoles and 1

  描述了基于恶唑 2 (OL-135) 的一系列精制 α-酮杂环的合成和评估，其中包含在带有一组关键添加取代基的中心杂环中的系统变化。中心杂环的性质，即使在本文探讨的系统和轻微扰动中，也会显着影响抑制剂活性：1,3,4-恶二唑和 1,2,4-恶二唑 9 > 四唑，异构体 1,2,4-恶二唑 10, 1,3,4-噻二唑 > 恶唑，包括 2 > 1,2-二嗪 > 噻唑 > 1,3,4-三唑。在这些趋势中最明显的是观察到在位置 4（恶唑编号，N > O > CH）引入额外的杂原子会显着增加活性，这可能归因于 FAAH 活性位点的不稳定空间相互作用减少。添加的显示明确趋势的杂环取代基可用于增强抑制剂效力，更重要的是增强抑制剂选择性。本文举例说明的这些趋势来自 FAAH 活性的增强和对竞争性脱靶酶的结合亲和力的同时破坏。
• Oxadiazole ketone inhibitors of fatty acid amide hydrolase
  申请人：Boger L. Dale

  公开号：US20080096931A1

  公开（公告）日：2008-04-24

  Certain oxadiazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as MS).

  某些氧代二唑酮化合物可用作FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、疾病和病情的方法。因此，这些化合物可以用于治疗焦虑、疼痛、炎症、睡眠障碍、进食障碍或运动障碍（如多发性硬化症）。
• ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS
  申请人：Boger Dale L.

  公开号：US20110183947A1

  公开（公告）日：2011-07-28

  The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for the preparation of compounds of formula (I), and methods of using compounds of formula (I) and compositions thereof.

  本发明提供了一系列-α酮杂环化合物，例如，公式（I）的化合物。这些化合物可以抑制脂肪酸酰胺水解酶，并可用于治疗由脂肪酸酰胺水解酶调节的异常情况。本发明还提供了制备公式（I）化合物的方法，用于制备公式（I）化合物的有用中间体，以及使用公式（I）化合物及其组成物的方法。
• US7351724B2
  申请人：——

  公开号：US7351724B2

  公开（公告）日：2008-04-01
• US8987312B2
  申请人：——

  公开号：US8987312B2

  公开（公告）日：2015-03-24